A small cap biotech reported Wednesday that the Russian invasion of Ukraine will delay the interim analysis for a large study, suggesting the war could bring new challenges to the industry. Tricida said Wednesday afternoon it will have to delay the data readout for its experimental CKD drug veverimer by